Search Results - "MAYER, Jiří"

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial by Cortes, Jorge E, Saglio, Giuseppe, Kantarjian, Hagop M, Baccarani, Michele, Mayer, Jiří, Boqué, Concepción, Shah, Neil P, Chuah, Charles, Casanova, Luis, Bradley-Garelik, Brigid, Manos, George, Hochhaus, Andreas

“…We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial,…”
Get full text

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials by Bussel, James, Arnold, Donald M., Grossbard, Elliot, Mayer, Jiří, Treliński, Jacek, Homenda, Wojciech, Hellmann, Andrzej, Windyga, Jerzy, Sivcheva, Liliya, Khalafallah, Alhossain A., Zaja, Francesco, Cooper, Nichola, Markovtsov, Vadim, Zayed, Hany, Duliege, Anne‐Marie

“…Spleen tyrosine kinase (Syk) signaling is central to phagocytosis‐based, antibody‐mediated platelet destruction in adults with immune thrombocytopenia (ITP)…”
Get full text

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3 - mutated acute myeloid leukemia patients - Czech center experience by Weinbergerová, Barbora, Čerňan, Martin, Kabut, Tomáš, Semerád, Lukáš, Podstavková, Natália, Szotkowski, Tomáš, Ježíšková, Ivana, Mayer, Jiří

Get full text

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin by Kuželová, Kateřina, Brodská, Barbora, Schetelig, Johannes, Röllig, Christoph, Ráčil, Zdeněk, Walz, Juliane Stickel, Helbig, Grzegorz, Fuchs, Ota, Vraná, Milena, Pecherková, Pavla, Šálek, Cyril, Mayer, Jiří

“…Acute myeloid leukemia with mutated nucleophosmin (NPMc+ AML) forms a distinct AML subgroup with better prognosis which can potentially be associated with…”
Get full text

Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options by Eid, Michal, Foukal, Jakub, Sochorová, Dana, Tuček, Štěpán, Starý, Karel, Kala, Zdeněk, Mayer, Jiří, Němeček, Radim, Trna, Jan, Kunovský, Lumír

“…Pheochromocytomas (PCCs) are rare neuroendocrine tumors derived from the chromaffin cells of the adrenal medulla. When these tumors have an extra‐adrenal…”
Get full text

MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia by Šestáková, Šárka, Šálek, Cyril, Kundrát, Dávid, Cerovská, Ela, Vydra, Jan, Ježíšková, Ivana, Folta, Adam, Mayer, Jiří, Cetkovský, Petr, Remešová, Hana

“…Changes in DNA methylation are common events in the pathogenesis of acute myeloid leukemia (AML) and have been repeatedly reported as associated with…”
Get full text

The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma by Eid, Michal, Karousi, Paraskevi, Kunovský, Lumír, Tuček, Štěpán, Brančíková, Dagmar, Kala, Zdeněk, Slabý, Ondřej, Mayer, Jiří, Kontos, Christos K., Trna, Jan

“…Pancreatic ductal adenocarcinoma (PDAC) is increasing in incidence and is still associated with a high rate of mortality. Only a minority of patients are…”
Get full text

A novel germline mutation in GP1BA gene N-terminal domain in monoallelic Bernard-Soulier syndrome by Trizuljak, Jakub, Kozubík, Kateřina Staňo, Radová, Lenka, Pešová, Michaela, Pál, Karol, Réblová, Kamila, Stehlíková, Olga, Smejkal, Petr, Zavřelová, Jiřina, Pacejka, Milan, Mayer, Jiří, Pospíšilová, Šárka, Doubek, Michael

“…Mutations in the GP1BA gene have been associated with platelet-type von Willebrand disease and Bernard-Soulier syndrome. Here, we report a novel GP1BA mutation…”
Get full text

P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA by Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva‐Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Kiladjian, Jean‐Jacques

Get full text

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data by Saglio, Giuseppe, Kantarjian, Hagop M., Shah, Neil, Jabbour, Elias J., Quintas-Cardama, Alfonso, Steegmann, Juan Luis, Boqué, Concepción, Chuah, Charles, Pavlovsky, Carolina, Mayer, Jiří, Ukropec, Jon, Wildgust, Mark, Hochhaus, Andreas

“…Abstract 1675 In the randomized phase 3 DASISION trial in patients (pts) with newly diagnosed CML-CP, dasatinib 100 mg once daily (QD) demonstrated improved…”
Get full text

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) by Jabbour, Elias, Kantarjian, Hagop M., Saglio, Giuseppe, Steegmann, Juan Luis, Shah, Neil P., Boqué, Concepción, Chuah, Charles, Pavlovsky, Carolina, Mayer, Jiří, Cortes, Jorge, Baccarani, Michele, Kim, Dong-Wook, Bradley-Garelik, M. Brigid, Mohamed, Hesham, Wildgust, Mark, Hochhaus, Andreas

“…This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase…”
Get full text

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia by Jurczak, Wojciech, Chojnowski, Krzysztof, Mayer, Jiří, Krawczyk, Katarzyna, Jamieson, Brian D., Tian, Wei, Allen, Lee F.

“…Summary Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6‐month, multicentre, randomised, double‐blind, parallel‐group…”
Get full text

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia by Wierda, William G, Kipps, Thomas J, Mayer, Jirí, Stilgenbauer, Stephan, Williams, Cathy D, Hellmann, Andrzej, Robak, Tadeusz, Furman, Richard R, Hillmen, Peter, Trneny, Marek, Dyer, Martin J S, Padmanabhan, Swami, Piotrowska, Magdalena, Kozak, Tomas, Chan, Geoffrey, Davis, Randy, Losic, Nedjad, Wilms, Joris, Russell, Charlotte A, Osterborg, Anders

“…New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with…”
Get full text

Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults by Červinek, Libor, Mayer, Jiří, Doubek, Michael

“…Thrombopoietin-receptor agonists (TPO-RAs) are highly effective in immune thrombocytopenia (ITP). Recently, reports of sustained remission after TPO-RA…”
Get full text

High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience by Kabut, Tomáš, Weinbergerová, Barbora, Folber, František, Lengerová, Martina, Mayer, Jiří

“…There is only limited data on cytomegalovirus (CMV) prophylaxis with high-dose (HD) aciclovir after allogeneic hematopoietic stem cell transplantation…”
Get full text

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia by KANTARJIAN, Hagop M, THOMAS, Xavier G, KUO, Ching-Yuan, ORIOL, Albert, RAVANDI, Farhad, FADERL, Stefan, DELAUNAY, Jacques, LYSAK, Daniel, MINDEN, Mark, ARTHUR, Christopher, DMOSZYNSKA, Anna, WIERZBOWSKA, Agnieszka, MAZUR, Grzegorz, MAYER, Jiri, GAU, Jyh-Pyng, CHOU, Wen-Chien, BUCKSTEIN, Rena, CERMAK, Jaroslav

“…This multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients with…”
Get full text

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b by Kiladjian, Jean-Jacques, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Gisslinger, Heinz

Get full text

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma by Robak, Tadeusz, Huang, Huiqiang, Jin, Jie, Zhu, Jun, Liu, Ting, Samoilova, Olga, Pylypenko, Halyna, Verhoef, Gregor, Siritanaratkul, Noppadol, Osmanov, Evgenii, Alexeeva, Julia, Pereira, Juliana, Drach, Johannes, Mayer, Jiri, Hong, Xiaonan, Okamoto, Rumiko, Pei, Lixia, Rooney, Brendan, van de Velde, Helgi, Cavalli, Franco

“…The substitution of bortezomib for vincristine in R-CHOP resulted in higher rates of complete response and nearly a doubling in progression-free survival among…”
Get full text

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial by Sehn, Laurie H, Dr, Chua, Neil, MD, Mayer, Jiri, Prof, Dueck, Gregg, MD, Trněný, Marek, Prof, Bouabdallah, Kamal, MD, Fowler, Nathan, MD, Delwail, Vincent, MD, Press, Oliver, Prof, Salles, Gilles, MD, Gribben, John, Prof, Lennard, Anne, MBBS, Lugtenburg, Pieternella J, MD, Dimier, Natalie, MSc, Wassner-Fritsch, Elisabeth, PharmD, Fingerle-Rowson, Günter, MD, Cheson, Bruce D, Prof

“…Summary Background Patients with indolent non-Hodgkin lymphoma who fail to achieve adequate disease control with rituximab-based treatment have few treatment…”
Get full text

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment by Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Kiladjian, Jean-Jacques

Get full text